Sodium Bicarbonate Injection USP recalled for lack of sterility assurance
Nephron Sterile Compounding Center recalls 36,354 pre-filled syringes of Sodium Bicarbonate Injection due to lack of sterility assurance. The medication was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an injectable drug with potential contamination risk due to lack of sterility assurance. Although no illnesses or injuries have been reported, the product category (sterile injectable) and nature of the hazard (uncertain sterility) present significant risk of harm if the product is used, meeting the criterion for High (score 3).
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Sodium Bicarbonate Injection USP in pre-filled syringes due to lack of assurance of sterility. Approximately 36,354 syringes from 14 affected lots (SB2001B through SB2009B, with expiration dates from January to April 2023) are subject to this recall.
The FDA classified this as a Class II recall. The product was distributed nationwide in the United States.
Healthcare providers should verify lot numbers and expiration dates against the affected lots listed in the recall. Doses from the recalled lots should not be used. Patients and providers should contact the manufacturer or FDA for additional information and guidance.
The recalled product
- Product
- 8.4% Sodium Bicarbonate Injection, USP, 4.2 g/50 mL (84 mg/mL) 1 mEq/mL syringe, packaged in 1 x 50 mL Pre-Filled Syringe per carton, 30 x 1 syringe carton per case, Rx Only Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-214-50
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable Medication
- Hazard
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lots: SB2001B
- Exp. 1/2/2023
- SB2001C
- SB2003A
- Exp. 2/14/2023
- SB2003B
- SB2003C
- SB2004A
- Exp. 3/1/2023
- SB2004B
- SB2004C
- SB2005A
- Exp. 3/8/2023
- SB2007A
- Exp. 3/22/2023
- SB2007B
- SB2008A
- Exp. 3/29/2023
- SB2008B
- SB2009A
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27